Randomized Trial Of Standard Chemotherapy Alone Or Combined With Atezolizumab As Adjuvant Therapy For Patients With Stage III Colon Cancer And Deficient DNA Mismatch Repair
This phase III trial studies combination chemotherapy and atezolizumab to see how well it
works compared with combination chemotherapy alone in treating patients with stage III colon
cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination
chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such
as atezolizumab, may help the body''s immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving combination chemotherapy with
atezolizumab may work better than combination chemotherapy alone in treating patients with
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.